BioSpace News Archive

The first quarter has been characterized by intensive work with our clinical trial program; PHSU05, a Phase II study with PXL01 for prevention of skin scarring.

Zealand Pharma Announces Asset Purchase Agreement withMannKind Corporation forV-Go®Insulin Delivery Device

MannKind Corporation announced that it has entered into an agreement with Zealand Pharma A/S to acquire V-Go® for $10 million, with additional sales-based milestones plus the cost of certain inventory.

International Stem Cell Corporation, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, provided a business update and financial results for the three months ended March 31, 2022.

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced the appointment of Dirk Benson to the position of Vice President and Chief Commercial Officer of the Company’s North America Distribution Group.

Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, announced the close of a $70 million Series B financing.

Vertex Pharmaceuticals Incorporated announced that Vertex and the Vertex Foundation, a nonprofit charitable foundation, have committed $50 million over five years to clinical trial diversity, access to quality care, and education of our health care workforce.

Evotec SE and Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics announced a partnership in the field of diabetes.

RQ Bio emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio’s existing mAbs against SARS-CoV-2.

Sosei Group Corporation, the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases.